Hepatitis B Infections in Individuals with Exposure Factors in Quibdo and Apartado, Colombia

David Ríos Patiño MD,1 Diana di Filippo V., MSc,1 Margarita Insuasty E., MD,1 Julio C. Rendón L., MSc,1 Wilson Alfredo Ríos O., MSc,1 Carlos Medina L., Biol,1 María Cristina Hoyos, MSc,1 Carlos Julio Montoya G., MD, PhD,2 María Cristina Navas N., MSc, PhD.1

Abstract
Introduction: Colombia has a varied geographical pattern of prevalence of hepatitis B virus (HBV) infections with regions of high, moderate and low prevalences.

Objective: The objective of this study was to identify cases of HBV infection and characterize viral genotypes in population with factors of exposure in the cities of Quibdo and Apartado, Colombia.

Materials and Methods: The study population included 768 asymptomatic individuals with factors of exposure to HBV infections. An HBV surface antigen (HBsAg) rapid detection test was the first test used. Samples from individuals who tested positive were tested with ELISA to confirm the diagnosis and with PCR to detect the HBV genome. Viral genotypes were determined by sequencing and phylogenetic analysis.

Results: Seventeen individuals (17/768, 2.2%) were diagnosed with HBV infections by both the Rapid Test and Elisa. Phylogenetic analyses allowed identification of genotypes F (F3 and Subgenotype F1a) and A in the samples.

Conclusions: We report for the first time the presence of the F1a subgenotype in Colombia and confirm the presence of subgenotype F3 and genotype A.

Keywords
Hepatitis B, Epidemiology, risk factors, genotypes.

INTRODUCTION

Globally, infection with Hepatitis B Virus (HBV) is a public health problem. In January, the World Health Organization (WHO) estimated that there are more than 240 million cases of chronic HBV infections. HBV carries the risk of developing into cirrhosis and hepatocellular carcinoma (HCC) (1).

HBV is classified in the Hepadnaviridae family. Its genome consists of a circular DNA (deoxyribonucleic acid) molecule that is a partial double strand encoding seven proteins (surface antigens (HBsAg), core antigens (HBcAg), antigen E, viral polymerase and protein X) (2, 3).

The prevalence of HBsAg was used to define the country’s regions as having low, intermediate or high levels of HBV endemicity (4). Colombia has a heterogeneous pattern of prevalence, but as of April, its overall endemicity was considered to be moderate (4).

Currently ten HBV genotypes have been characterized (genotypes A through J) (5-8). A correlation between certain genotypes of HBV and variables such as transmission efficiency, tendency to chronicity, response to antiviral therapy and progression to cirrhosis and HCC has been suggested (9). For example, genotype C is associated with a higher risk of HCC than is genotype B. Also, infections with genotypes A and B respond better to interferon treatment than do infections with genotypes C and D (9).

Studies of blood donors and patients with terminal liver disease have identified Genotype F and subgenotype F3 as the most frequently occurring genotypes in Colombia. In
addition, genotypes A, D, C and G have been described, but at lower frequencies (10-12). Genotype E has been identified in pregnant Afro-Colombian women, and subgenotype F1b has been identified among indigenous people (13-15).

This study aims to identify cases of HBV infection and characterize viral genotypes in an asymptomatic population with exposure factors in the municipalities of Quibdó and Apartadó, Colombia.

MATERIALS AND METHODS

Study Population

Between September and November 2009, a study was conducted in an asymptomatic population in Quibdó, the capital of the department of Chocó, and Apartadó, a municipality in Antioquia Department. The study population was selected by the hospitals in these cities according to risk factors such as blood transfusion, surgery, sexually transmitted diseases (STDs) and family histories of hepatitis. Prior to signing of informed consent form by patients, or a parent or guardian in the case of minors, a researcher explained the purpose of the study. After administration of the HBsAg rapid detection test, a researcher provided advice participants who tested positive. The researcher provided HBV infection risk factors, the likelihood of chronic infection, sequelae of infection, testing to confirm the diagnosis, and treatment. The study was approved by the ethics committee of the Fundación Antioqueña de Infectología.

Rapid Test for detection of HBsAg

A total 768 people in urban and rural areas of Apartadó and Quibdó agreed to participate in the study. A sample of whole blood was obtained by puncture with a lancet from each of the participants, and a rapid test for the detection of HBV surface antigen (HBsAg) (One Step HBsAg Rapid Test Kit) (Intec, China) was performed according to the manufacturer’s recommendations.

Detection of Viral Genome

All DNA from serum samples was extracted by the Trizol method (Invitrogen, USA), following the instructions of the manufacturer. Open reading frame (ORF) S of HBV (S region, nucleotides 203-787) was amplified. Amplification conditions were adapted from published protocols (16). Both rounds of PCR reaction were performed in final volumes of 25ul (1X Buffer, 50 mM MgCl₂, 2.5 mM dNTPs (Promega), 10 uM primers and 50 U/ul of Biolase DNA polymerase (Bioline)). In the first round of PCR, S1R and PRsS2 primers were used. In the second round, YS1 and YS2 were used. (16) PCR conditions were 93° C for 3 min, 35 cycles at 94° for 45 sec, 53° C for 1 min, 72 ° C for 1:30 min, and a final extension step at 72 ° C for 6 min. The amplified fragment of 585 base pairs (bp) was visualized on 2% agarose gel stained with ethidium bromide. DNA obtained from a liver explant (TH79) from a patient with chronic HBV infection was used as a positive control of testing. Nuclease free water (Invitrogen, Ambion® Nuclease-Free Water) was used as the negative control.

Genotyping of HBV

PCR products were purified and sequenced by the automated dideoxynucleotide method (Big Dye TM Terminator, Macrogen, Korea). The sequences obtained were compared to published HBV sequences from the GenBank. Sequences were aligned with ClustalW which is contained in Bioedit 7.0.5.3. Phylogenetic analysis was done with the Neighbor Joining and Maximum Parsimony method using MEGA 5.0 with 80 HBV sequences from GenBank. The reliability of the trees was evaluated using bootstrap values from 1,000 replicates.

Statistical Analysis

An Excel database was developed with the information obtained from the surveys and was subsequently analyzed using EPI-INFO and EPI-DAT. The prevalence ratio was calculated with a 95% confidence interval considering p <0.05 to be statistically significant.

RESULTS

Study Population

A total of 768 individuals participated in the study, 394 people (51.3%) enrolled during a visit to Apartadó and 374 people (48.6%) enrolled during two visits to Quibdó. Of the study population, 50.8% were male and 49.2% were female: the average age was 34 years with a 95% CI of 23 to 45.
The main factors of HBV exposure in the study population were surgery (41.1%), more than one sexual partner in the last six months (23.4%), STDs (18.7%), family histories of hepatitis (18.9%) and blood transfusions (8.6%). According to the surveys, at least 1 dose of hepatitis B vaccine had been received by 59.3% of the participants although it is worth mentioning that this information was not corroborated by vaccination papers. There were marked differences in vaccinations reported: 43.1% in Quibdó and 75.2% in Apartadó (Table 1).

Of the total population, 17 individuals (2.2%) tested positive with the HBsAg Rapid Test and ELISA. Eight (2.03%) were from Apartadó, and nine (2.4%) were from Quibdó. The average age of those who tested positive was 18 years with an age range of 19 to 77 years. Ten of those who tested positive were 10 men, and seven were women. The two main exposure factors of in the 17 cases were the absence of vaccination (8 cases) and family histories of hepatitis (6 cases). This second factor was so important in this study because five of the cases involved members of the same family in Apartadó, while in Quibdó none of the cases were related to each other (Table 2). Other exposure factors identified were surgery (4 cases), blood transfusions (3 cases) and STDs (3 cases).

**Detection of Viral Genome and HBV Genotypes**

The viral genomes of eight out of the seventeen (47.05%) serum samples from the individuals who tested positive with the HBsAg rapid test were amplified. This frequency of detection may be due to serum viral loads lower than the detection limit for the amplification technique (100 IU/mL) (16).

Phylogenetic analyses of the sequences showed the presence of genotype F in four samples (50%) of which three samples were identified as subgenotype F1b, and one was identified as subgenotype F1a. The four remaining samples (50%) were all characterized as genotype A. All samples from the municipality of Apartadó were genotype F, subgenotype F3. Four of the samples from Quibdó were classified as genotype A and two samples were classified as genotype F, one of which was subgenotype F3 while the other was subgenotype F1a (Table 3).

**DISCUSSION**

Quibdo’s population of 162,803 inhabitants consists mainly of people of African descent with varying degrees of mixture with other groups. Apartadó is located in nor-

---

**Table 1. Sociodemographic Variables and HBV exposure factors in the study population from the municipalities of Apartadó and Quibdó.**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total (n=768)</th>
<th>Quibdó (n=374)</th>
<th>Apartadó (n=394)</th>
<th>RR</th>
<th>CI (Confidence Interval)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>34±16</td>
<td>37 ± 17</td>
<td>32 ± 16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Masculine</td>
<td>390 (50.8%)</td>
<td>197 (52.7%)</td>
<td>193 (49%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feminine</td>
<td>375 (48.8%)</td>
<td>176 (47.1%)</td>
<td>199 (50.5%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No data</td>
<td>3 (0.4%)</td>
<td>1 (0.2%)</td>
<td>2 (0.5%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethnicity a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Afro-descendent</td>
<td>385 (50.1%)</td>
<td>290 (77.5%)</td>
<td>95 (24%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mestizo</td>
<td>311 (40.5%)</td>
<td>59 (15.8%)</td>
<td>252 (64%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>21 (2.7%)</td>
<td>19 (5.1%)</td>
<td>2 (0.5%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indigenous</td>
<td>6 (0.8%)</td>
<td>3 (0.8%)</td>
<td>3 (0.8%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No data</td>
<td>45 (5.9%)</td>
<td>3 (0.8%)</td>
<td>42 (10.7%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk Factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>316 (41.1%)</td>
<td>153 (40.9%)</td>
<td>163 (41.4%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STD</td>
<td>145 (18.8%)</td>
<td>80 (21.4%)</td>
<td>65 (16.5%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood Transfusion</td>
<td>67 (8.7%)</td>
<td>42 (11.2%)</td>
<td>25 (6.3%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family History of Hepatitis B</td>
<td>146 (19%)</td>
<td>68 (18.2%)</td>
<td>78 (19.8%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>More than 1 sexual partner within six months</td>
<td>181 (23.5%)</td>
<td>107 (28.6%)</td>
<td>74 (18.8%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B Vaccination</td>
<td>256 (33.3%)</td>
<td>104 (27.8%)</td>
<td>152 (38.5%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a: Subjective Appreciation of interviewer
b: According to information provided by the participant but uncorroborated by vaccination papers

**Table 2. Exposure factors in individuals with HBV**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Total</th>
<th>Quibdó</th>
<th>Apartadó</th>
<th>RR</th>
<th>CI (Confidence Interval)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>0.27</td>
<td>0.24-1.34</td>
<td>0.21</td>
</tr>
<tr>
<td>Blood Transfusion</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>2.25</td>
<td>0.63-7.63</td>
<td>0.18</td>
</tr>
<tr>
<td>STD</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>1.3</td>
<td>0.43-3.93</td>
<td>0.55</td>
</tr>
<tr>
<td>Family History of Hepatitis B</td>
<td>6</td>
<td>0</td>
<td>6</td>
<td>2.2</td>
<td>0.89-6.07</td>
<td>0.12</td>
</tr>
<tr>
<td>More than 1 sexual partner within six months</td>
<td>6</td>
<td>4</td>
<td>2</td>
<td>1.74</td>
<td>0.65-4.65</td>
<td>0.26</td>
</tr>
<tr>
<td>No HBV Vaccination</td>
<td>8</td>
<td>4</td>
<td>4</td>
<td>0.59</td>
<td>0.14-2.34</td>
<td>0.51</td>
</tr>
</tbody>
</table>
vided information derived from individual reports of HBV. The reported incidences in the departments of Antioquia and Chocó from 2008 to 2012 may be due to the quality of reporting (Table 5) (21).

Table 5. Incidence of Hepatitis B in the departments of Antioquia and Chocó between 2008 and 2012 according to the National Institutes of Health.

<table>
<thead>
<tr>
<th>Territory</th>
<th>Incidence (cases/100,000 people)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2008</td>
</tr>
<tr>
<td>Colombia</td>
<td>3</td>
</tr>
<tr>
<td>Antioquia</td>
<td>4.4</td>
</tr>
<tr>
<td>Chocó</td>
<td>1.9</td>
</tr>
</tbody>
</table>

As of the fifth week of 2013, the incidence of Hepatitis B in Colombia was 1.84 cases per 100,000 inhabitants, but there were great variations among the country’s regions. The incidence of HBV in the department of Antioquia in 2013 was 2.29 cases per 100,000 people while in Chocó it was 3.06 cases per 100,000 people (22).

In this study 17 cases (2.2%) of HBV infections were identified from a total of 768 individuals with risk factors. The percentage in Apartadó was 2.03% while it was 2.4% in Quibdó. Prevalence studies of HBV in Quibdó and Apartadó in 1987 and 1988 reported a frequency of HBsAg of 11% in the general population and among health personnel in Apartadó and in two other municipalities in the region of Urabá, as well as a prevalence of 7% in the rural population of Quibdó (19, 20).

As mentioned in the methodology section, cases of HBV were first identified with a rapid test for HBsAg the technical specifications of which state that it has high sensitivity and specificity. Nevertheless, this research group evaluated the test’s sensitivity and specificity in a separate study after

Table 4. Percentage of population with unmet basic needs (INBI) in Quibdó and Apartadó in July 2010 according to statistics from DANE (Departamento Administrativo Nacional de Estadística - National Administrative Department of Statistics)

<table>
<thead>
<tr>
<th>Region</th>
<th>People in a state of misery 1</th>
<th>People with unmet basic needs 2</th>
<th>Housing Component a</th>
<th>Service Component b</th>
<th>Housing Density Component c</th>
<th>Inassistance Component d</th>
<th>Economic dependence Component e</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quibdó</td>
<td>29.33</td>
<td>89.47</td>
<td>7.48</td>
<td>88.24</td>
<td>11.29</td>
<td>5.64</td>
<td>17.22</td>
</tr>
<tr>
<td>Apartadó</td>
<td>9.00</td>
<td>24.53</td>
<td>8.19</td>
<td>2.01</td>
<td>13.76</td>
<td>3.73</td>
<td>9.81</td>
</tr>
</tbody>
</table>

1) A home that has a basic lack is considered a home with basic needs.
2) When a household has two or more deficiencies, it is considered to be in a state of misery.
A) Mobile homes, home located in natural refuges or under bridges, homes without walls or with walls made of fabric or waste materials, and homes with dirt floors.
B) Lack of health care services and water including when water from rivers, springs, rainwater or tank cars is used.
C) More than three people per room.
D) Households in which one or more children between 7 and 11 years old who are relatives of the head of household do not attend a formal education center.
E) Households with more than three people per employed household member and in which the head of the household has finished two years of primary education at most.
Hepatitis B Infections in Individuals with Exposure Factors in Quibdo and Apartado, Colombia

Figure 1. Phylogenetic tree with root ORF S of HBV. The sequences from the study in Quibdo (●) and Apartado (▲) were compared with representative sequences of HBV genotypes (AI). The sequences are denoted with a GenBank accession number, genotype, country and the year in which they were reported. The tree was generated using the MEGA 5.1 Neighbor Joining method. Bootstrap values (indicated by Arabic numerals) were obtained from 1000 replicates. Values greater than 50 are in the “outgroup”. The AF046996 sequence isolated from Woolly Monkey Hepatitis B and the sequence isolated from the positive control used in the in amplification assays of this study are marked SueroCntP (○).

In this study we demonstrate the presence of genotype F (4/8; 50%), subgenotype F3 (3/4; 75%) subgenotype F1a (1/4; 25%), and genotype A (4/8; 50%) (Figure 1).
A study of blood donors in the cities of Bogota and Bucaramanga found a predominance of genotype F (subgenotype F3) (86%; 43/50) with lower frequencies of genotype D (8%; 4/50), C (2%; 1/50) and G (2%; 1/50). Cortes, Mancera and colleagues have characterized HBV isolated from patients diagnosed with cirrhosis and/or HCC and found a predominance of genotype F, subgenotype F3 (83.3%; 5/6) in the study population. Subgenotype F1a (16.7%; 1/6) was described in a sample from a foreign patient from El Salvador (11).

This study describes for the first time the circulation of subgenotype F1a in Colombia. This finding was unexpected because subgenotype F1a had previously been described only in Central America (9). However, recently some isolates of this subgenotype have been described in South American countries such as Peru (24). The results of this and these other studies suggest that subgenotype F1 is circulating in South American countries as a minority variant.

Recently, Alvarado and colleagues identified HBV genotypes in samples of blood donors in Bogotá, Bucaramanga, Neiva, Tunja and Pasto. Genotype F was the most prevalent (77%; 40/52) which included subgenotype F3 (75%; 39/52), followed by genotype A2 (15.3%; 8/52) and genotype G (7.7%, 4 / 52). In addition, the circulation of subgenotype F1b was described in 2% (1/52) of the samples. (12) Two recent studies describe genotype F1b in the indigenous population of the department of Amazonas (14, 15, 25).

The predominance of genotype F in South and Central America suggests that it is indigenous to the Americas (26-29). In fact, its distribution is directly related to migration patterns and to the dispersal of the first settlers of the Americas. Genetic studies suggest that populations of Colombia and Venezuela have a larger Amerindian genetic component (90%) than do Brazilian populations in which genotypes A and D are the most common. (30-34). This would explain the predominance of genotype F in Colombia and Venezuela.

On the other hand, genotype A has been reported in some South American countries like Venezuela and Brazil, specifically in African-descendant populations. Some researchers suggest that genotype A may have been introduced in America through the slave trade in African people during the eighteenth century (31). This would explain the fact that this HBV genotype was most frequent in Quibdó where most of the people are of African descent.

**CONCLUSION**

In conclusion, seventeen cases of infection were identified in the study population by the rapid HBV test. All were older individuals. The circulation of genotypes F and A in these populations is consistent with what has been reported by previous studies in Colombia in which the ethnic diversity of these regions seems to influence the geographic distribution of genotypes. Additional studies are needed to establish the importance of certain risk factors such as familial transmission of HBV in the town of Apartadó.

**Acknowledgements**

Sustainability Strategy for 2009-2010 of the Office of the Vice-Rector for Research at the Universidad de Antioquia; Bristol-Myers Squibb Pharmaceutical Company; Fundación Antioqueña de Infectologia

**REFERENCES**


